MDGL
Madrigal Pharmaceuticals, Inc.
$517.26
+3.67
(+0.71%)
Mkt Cap
11.93B
Volume
156,538
52W Range
265-615
Sector
Healthcare
Beta
-1.04
EPS (TTM)
-12.80
P/E Ratio
-45.32
Revenue (TTM)
1.13B
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 958.40M | 180.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (288.28M) | (465.89M) | (373.63M) | (295.35M) | (241.85M) | (202.24M) | (83.95M) | (32.81M) | (31.15M) | (26.39M) | (6.84M) | (86.16M) |
| EPS | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 |
| Free Cash Flow | (190.02M) | (457.03M) | (325.71M) | (225.07M) | (184.13M) | (157.90M) | (41.80M) | (25.53M) | (22.44M) | (17.61M) | N/A | N/A |
| FCF / Share | -8.47 | -21.48 | -17.43 | -13.13 | -11.14 | -10.22 | -2.71 | -1.73 | -1.83 | -3.38 | N/A | N/A |
| Operating CF | (189.55M) | (455.57M) | (324.23M) | (224.86M) | (183.92M) | (157.56M) | (41.62M) | (25.51M) | (22.32M) | (17.61M) | N/A | N/A |
| Total Assets | 1.26B | 1.04B | 640.55M | 362.57M | 273.33M | 287.00M | 442.06M | 485.43M | 192.31M | 41.21M | N/A | N/A |
| Total Debt | 354.36M | 119.57M | 117.19M | 49.89M | 797,000 | 786,000 | 676,000 | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 198.69M | 100.02M | 99.92M | 331.55M | 36.27M | 54.00M | 46.70M | 57.38M | 148.63M | 40.50M | N/A | N/A |
| Book Value | 602.69M | 754.38M | 405.33M | 197.39M | 196.11M | 239.97M | 416.56M | 476.98M | 182.26M | 36.41M | N/A | N/A |
| Return on Equity | -0.48 | -0.62 | -0.92 | -1.50 | -1.23 | -0.84 | -0.20 | -0.07 | -0.17 | -0.72 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 311.34M | 321.08M | 287.27M | 212.80M | 137.25M | 103.32M | 62.17M | 14.64M | 0 | 0 | 0 | 0 |
| Net Income | (94.39M) | (58.58M) | (114.19M) | (42.28M) | (73.24M) | (59.42M) | (106.96M) | (151.97M) | (147.54M) | (112.19M) | (98.74M) | (85.80M) |
| EPS | -3.25 | -2.57 | -5.08 | -1.90 | -3.32 | -2.71 | -4.92 | -7.10 | -7.38 | -5.68 | -5.34 | -4.69 |
| Free Cash Flow | (171.28M) | (133.07M) | 78.99M | (47.05M) | (88.89M) | (104.68M) | (67.76M) | (140.08M) | (149.51M) | (80.97M) | (85.26M) | (75.38M) |
| FCF / Share | -5.90 | -5.93 | 3.51 | -2.12 | -4.02 | -4.77 | -3.12 | -6.54 | -7.47 | -4.10 | -4.61 | -4.12 |
| Operating CF | (167.44M) | (133.46M) | 79.85M | (47.05M) | (88.89M) | (104.49M) | (66.98M) | (134.94M) | (149.16M) | (79.93M) | (84.92M) | (75.31M) |
| Total Assets | 1.23B | 1.26B | 1.36B | 1.02B | 996.63M | 1.04B | 1.07B | 1.10B | 1.08B | 640.55M | 237.96M | 302.46M |
| Total Debt | 347.31M | 354.36M | 346.40M | 123.95M | 119.77M | 119.57M | 119.14M | 118.06M | 117.72M | 117.19M | 116.56M | 99.66M |
| Cash & Equiv | 232.19M | 198.69M | 295.69M | 186.19M | 183.65M | 100.02M | 232.68M | 494.60M | 622.52M | 99.92M | 62.05M | 77.20M |
| Book Value | 543.45M | 602.69M | 625.73M | 695.98M | 710.64M | 754.38M | 777.15M | 857.12M | 850.76M | 405.33M | 22.25M | 103.51M |
| Return on Equity | -0.17 | -0.10 | -0.18 | -0.06 | -0.10 | -0.08 | -0.14 | -0.18 | -0.17 | -0.28 | -4.44 | -0.83 |
MDGL News
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
3 Biotech Stocks to Watch for Respectable Growth Beyond AI